Cell Therapy News Volume 27.18 | Oct 26 2026

    0
    24







    2026-10-26 | CTN 27.18


    Cell Therapy News by STEMCELL Technologies
    Vol. 27.18 – 26 October, 2026
    TOP STORY

    Determinants of Response to CAR T Cell Therapy in a Multicenter, Multi-Trial Cohort Analysis of Patients with Lymphoma

    Investigators analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel from 580 patients with non-Hodgkin lymphoma across multiple clinical trials with long-term follow-up.
    [Nature Medicine]

    Full Article
    Request your free EasySepâ„¢ sample and get a pair of highly coveted science socks.
    PUBLICATIONSListed by the impact factor of the journal

    In Vivo Engineering of CAR Natural Killer Cells for Immunotherapy Using Ligand-Directed Lipid Nanoparticles

    The authors developed NK cell-targeted lipid nanoparticles (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery. Systemic delivery of CAR mRNA using NtLNPs generates CAR NK cells in vivo.
    [Nature Biotechnology]

    Abstract

    CD8 T Cell Exhaustion Linked with CAR T Cell Failure Can Be Mitigated by a Non-Alpha IL2 Receptor Agonist

    Through single cell RNA-sequencing of tumors at the time of progression from CART19, investigators showed that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction.
    [Blood]

    Abstract

    Rapid CAR-T Manufacturing with Low-Intensity Priming Enhances CAR-T Cell Fitness and Limits Inflammatory Programming in a Phase I Study

    Scientists developed PrimeCAR, a two-day manufacturing strategy combining low-intensity anti-CD3 priming with IL-7 and IL-21. Functionally, PrimeCAR cells demonstrated enhanced expansion, persistence, and durable antitumor activity in xenograft models.
    [Cell Stem Cell]

    Abstract | Graphical Abstract

    CRISPRa Screen Unveils Noncanonical NF-κB to Boost the Antitumor Activity of TCR-Based CAR-T Cells

    To identify intrinsic persistence regulators in a TCR-based context, researchers performed an in vivo CRISPR activation screen in synthetic T cell receptor and antigen receptor T cells and identified the noncanonical NF-κB axis, with RELB as the top hit.
    [Cellular & Molecular Immunology]

    Abstract

    Local T Cell Engager Secretion Reprograms Endogenous Antitumor Immunity and Enhances CAR-T Cell Persistence in Solid Tumors

    Investigators compared conventional CAR-T cells, systemic T cell engagers, TCE-secreting (STAb)-T cells, and dual-targeting CAR–STAb-T cells in immunocompetent mouse models of high-grade glioma.
    [Journal for Immunotherapy of Cancer]

    Full Article | Graphical Abstract

    Locoregionally Delivered PD-1 Blockade Augments B7-H3 Targeting CAR T Cell Efficacy in Models of Glioblastoma

    Scientists identified B7-H3 as a favorable target antigen for CAR T cell therapy of glioblastoma and developed a B7-H3 targeting CAR T cell.
    [JCI Insight]

    Abstract
    REVIEWS

    Toward the Next Generation of CAR T Cell Therapies For Cancer

    Investigators summarize the clinical lessons learned from the now substantial experience with commercial CAR T cells and clinical trials and discuss three waves shaping next-generation development
    [Cancer Cell]

    Full Article

    T Cell Receptor-Engineered T Cell Therapy in Solid Tumors: Where We Stand and What’s to Come

    The authors summarize the biological rationale, clinical evidence, safety considerations, and resistance mechanisms of T cell receptor–engineered T cell therapy in solid tumors and discuss future directions to optimize their therapeutic potential.
    [Annual Review of Medicine]

    Abstract
    INDUSTRY AND POLICY NEWS

    Alex’s Lemonade Stand Foundation Funds 12 New Innovative Pediatric Cancer Grants

    Alex’s Lemonade Stand Foundation has funded 12 Innovation Grants to help researchers pursue bold ideas that could change the future of childhood cancer. Researchers are exploring new ways to overcome treatment resistance and uncover vulnerabilities that could lead to new therapies.
    [Alex’s Lemonade Stand Foundation for Childhood Cancer]

    Press Release

    Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

    Anixa Biosciences, Inc. announced that it has completed dosing of the fifth cohort in its ongoing Phase I, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
    [Anixa Biosciences, Inc. (BioSpace)]

    Press Release
    FEATURED EVENT

    Precision Genome Engineering: From Laboratory to Clinic

    January 25-27, 2027
    Keystone, Colorado, United States

    > See All Events

    JOB OPPORTUNITIES

    Advanced Practice Provider – Hematology and Medical Oncology

    Boston University Medical Campus – Boston, Massachusetts, United States

    Assistant or Associate Professor – Oncology / Anatomy & Cell Biology or Biochemistry

    Schulich School of Medicine & Dentistry, Western University – London, Ontario, Canada

    Postdoctoral Fellow – Cancer Immunotherapy

    University of Maryland School of Medicine – Maryland, Baltimore, United States

    Postdoctoral Research Associate – Immunology

    St Jude Children’s Research Hospital – Memphis, Tennessee, United States

    Assistant, Associate or Full Professor – Nuclear Medicine and Theranostics, Radiological Sciences, Oncology

    University of California Los Angeles – Los Angeles, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2


    1618 Station Street

    Vancouver, BC, V6A 1B6, Canada

    Unsubscribe or manage your subscriptions.

    View the Science News privacy policy here.